Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Evaluation of comorbidity in elderly patients before correction of valvular heart diseases

Authors: Pelekh D.M., Nikitina T.G., Gulyan K.S., Fadeev A.A., Golukhova E.Z.

Company:
Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/10.24022/1814-6910-2021-18-4-281-290

UDC: 616.126-089-008.6

Link: Clinical Physiology of Blood Circulaiton. 2021; 4 (18): 281-290

Quote as: Pelekh D.M., Nikitina T.G., Gulyan K.S., Fadeev A.A., Golukhova E.Z. Evaluation of comorbidity in elderly patients before correction of valvular heart diseases. Clinical Physiology of Circulation. 2021; 18 (4): 281–90 (in Russ.). DOI: 10.24022/1814-6910-2021-18-4-281-290

Received / Accepted:  23.08.2021 / 28.09.2021

Full text:  

Abstract

Objective. To conduct a preoperative assessment of comorbidity in elderly patients before correction of valvular heart disease (VHD) in conditions of artificial circulation.

Material and methods. 310 patients with VHD were assessed for the level of comorbidity using the Charlson Comorbidity Index (CCI). The patients were divided into 2 groups: 200 patients ≥ 60 years old (group I elderly, average age 66.3 ± 2.7 years) and 110 patients < 60 years (control group II, average age 56.3 ± 1.8 years). In group I, patients before surgery were assigned to functional class (FC) III 61.4% and IV FC 38.6% according to New-Yorks’ Heart Association (NYHA). The average EuroSCORE II (ES II) in the elderly is 18.2 ± 6.4%. In group II, FC III according to NYHA was assigned to 66.1%, to FC IV – 33.9% of patients. Average ES II in group II was 9.2 ± 1.1%. 23.1% of patients in group I and 31.1% of patients in group II underwent combined operations (correction VHD + coronary artery bypass graft).

Results. The mean CCI score in the elderly group was 5.7 ± 2.2, patients had ≥ 3 concomitant diseases: 100% had hypertension (blood pressure (BP) ≥ 140/90 mm Hg), 36% – ischemic heart disease (coronary artery disease – stenosis of the coronary arteries ≥ 65%), 21% – chronic kidney disease 3 degree (CKD grade 3 with GFR ≤ 50 ml/min/m2). In group II, the average score on the CCI questionnaire was 2.7 ± 1.5. 88% of patients had hypertension, 35.5% had coronary artery disease, 10.5% had CKD grade 3. Hospital mortality in group I – 6.5%, in group II – 2.7%. Predictors of hospital mortality in both groups: CCI ≥ 5 (OR = 1.1; p = 0.023), ES II ≥ 8% (OR = 1.4; p = 0.06), combined surgery (OR = 2.8; p = 0.017).

Conclusion. Evaluation of comorbidity is an important and independent element of risk stratification for surgical treatment of VHD under cardiopulmonary bypass in elderly patients with an initially high ES II (≥ 5%). According to our study, a high CCI score (≥ 3–6) is a predictor of the development of postoperative (p/o) complications and mortality in the early stages of p/o (up to 30 days after operation).

References

  1. Коморбидность: зависимость и другие психические заболевания. Роквилль, Мэриленд: Министерство здравоохранения и социальных служб США, Национальные институты здравоохранения, Национальный институт злоупотребления наркотиками; 2010. www.wikichi.ru
  2. Путилина М.В. Коморбидность у пациентов пожилого возраста. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016; 116 (5): 106–11. DOI: 10.17116/jnevro201611651106-111
  3. Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008; 8: 221. DOI: 10.1186/1471-2458-8-221
  4. Оганов Р.Г. Борьба с сердечно-сосудистыми заболеваниями – вклад государства, гражданского общества и человека. IX Всероссийский форум «Здоровье нации – основа процветания России». М.; 2015
  5. Australian Institute of Health and Welfare (AIHW): Chronic diseases and associated risk factors in Australia, 2006. Canberra, ACT; 2006.
  6. Лазебник Л.Б. Полиморбидность и старение. Новости медицины и фармации. 2007; 1 (205).
  7. Charlson M.E., Pompei P., Ales K.L., MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40: 373–83.
  8. Верткин А.Л., Ховасова Н.С., Белялов Ф. Коморбидный пациент. Руководство для практических врачей. М.: Эксмо; 2015.
  9. Кочетова Е.В. Оценка коморбидности у больных хронической обструктивной болезнью легких. Туберкулёз и болезни лёгких. 2017; 95 (4): 11–4. DOI: 10.21292/2075-1230-2017-95-4-11-14
  10. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011; 10 (6S2): 2–64.
  11. Conroy R.M., Pyorala K., Fitzgerald A., Sans P., Menotti A., De Backer G. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europa: the SCORE project. Eur. Heart J. 2013; 24: 987–1003. DOI: 10.1016/s0195-668x(03)00114-3
  12. Оганов Р.Г., Денисов И.Н., Симаненков В.И., Бакулина Н.В., Барбараш О.Л., Бойцов С.А. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017; 16 (6): 5–56. DOI: 10.15829/1728-8800-2017-6-5-56
  13. DuGoff E.H., Canudas-Romo V., Buttorff C., Bruce L., Anderson G. Multiple chronic conditions and life expectancy: a life table analysis. Med. Care. 2014; 52 (8): 688–94. DOI: 10.1097/MLR.0000000000000166
  14. Centers for Medicare & Medicaid Services. Chronic conditions overview. 2014. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics. Trends-and-Reports/Chronic Conditions/index.htm (accessed 20.07.2021)
  15. Оганов Р.Г., Симаненков В.И., Бакулин И.Г., Бакулина Н.В., Барбараш О.Л., Бойцов С.А. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 /li>
  16. Rocca W.A., Boyd C.M., Grossardt B.R., Bobo W.V., Finney L., Rutten J. et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin. Proc. 2014; 89 (10): 1336–49. DOI: 10.1016/j.mayocp.2014.07.010
  17. Chamberlain A.M., St Sauver J.L., Gerber Y., Manemann S.M., Boyd C.M., Dunlay S.M. et al. Multimorbidity in heart failure: a community perspective. Am. J. Med. 2015; 128 (1): 38–45. DOI: 10.1016/j.amjmed.2014.08.024
  18. Толпыгина С.Н., Марцевич С.Ю., Деев А.Д. Влияние сопутствующих заболеваний на отдаленный прогноз пациентов с хронической ишемической болезнью сердца по данным регистра «Прогноз ИБС». Рациональная фармакотерапия в кардиологии. 2015; 11 (6): 571–6. DOI: 10.20996/1819-6446-2015-11-6-571-576
  19. Оганов Р.Г. Сосудистая коморбидность: общие подходы к профилактике и лечению. Рациональная фармакотерапия в кардиологии. 2015; 11 (1): 4–7.
  20. Ахмедова Э.Б., Марданов Б.У., Бадейникова К.К., Мамедов М.Н. Исследование качества жизни и параметров клинико-биохимического спектра у больных артериальной гипертензией и коморбидными состояниями. Рациональная фармакотерапия в кардиологии. 2017; 13 (1): 31–5. DOI: 10.20996/1819-6446-2017-13-1-31-35
  21. Тавлуева Е.В., Ярковская А.П., Барбараш О.Л. Взаимосвязь сахарного диабета с провоспалительным статусом у женщин и мужчин с ИМПST. Комплексные проблемы сердечно-сосудистых заболеваний. 2014; 1: 42–6.
  22. Зыков М.В. Особенности течения и стратификации риска осложнений острого коронарного синдрома в сочетании с почечной дисфункцией и различной стратегией лечения (обзор литературы). Комплексные проблемы сердечно-сосудистых заболеваний. 2015; 3: 68–78.
  23. Сумин А.Н., Корок Е.В., Щеглова А.В., Барбараш О.Л. Коморбидность у больных ишемической болезнью сердца: гендерные особенности. Рациональная фармакотерапия в кардиологии. 2017; 13 (5): 622–9. DOI: 10.20996/1819-6446-2017-13-5- 622-629
  24. Шихвердиев Н.Н., Ушаков Д.И., Пелешок А.С., Кривопалов В.А., Сизенко В.В. Новые подходы в стратификации риска кардиохирургических больных пожилого возраста. Клиническая и экспериментальная хирургия. Журнал им. акад. Б.В. Петровского. 2019; 7 (1): 23–7. DOI: 10.24884/0042-4625- 2019-178-1-17-20
  25. Хасанова Л.Б., Комарова И.С., Андреева Н.В., Желнов В.В. Влияние мультиморбидности на приверженность лечению пациентов с инфарктом миокарда. Научные известия. 2018; 11: 86–91.
  26. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 2011; 364: 2187–98. DOI: 10.1056/NEJMoa1103510
  27. Keymel S., Hellhammer K., Zeus T., Merx M., Kelm M., Steiner S. et al. Severe aortic valve stenosis in the elderly: high prevalence of sleep-related breathing disorders. Clin. Interv. Aging. 2015; 10: 1451–6. DOI: 10.2147/CIA.S87189
  28. Lindman B.R., Patel J.N. Multimorbidity in older adults with aortic stenosis. Clin. Geriatr. Med. 2016; 32: 305–14. DOI: 10.1016/j.cger.2016.01.006
  29. Forman D.E., Maurer M.S., Boyd C., Brindis R., Salive M.E., Horne F.M., Rich M.W. Multimorbidity in older adults with cardiovascular disease. J. Am. Coll. Cardiol. 2018; 71 (19): 2149–61. DOI: 10.1016/j.jacc.2018.03.022
  30. Min H., Avramovic S., Wojtusiak J., Khosla R., Fletcher R.D., Alemi F. et al. A comprehensive multimorbidity index for predicting mortality in intensive care unit patients. J. Palliat. Med. 2017; 20: 35–41. DOI: 10.1089/jpm.2015.0392
  31. Ефремова Е.В., Шутов А.М., Серов В.А., Мензоров М.В. Коморбидность в клинической медицине: учебно-методическое пособие. Ульяновск: УлГУ; 2016. Efremova E.V., Shutov A.M., Serov V.A., Menzorov M.V. Comorbidity in clinical medicine: teaching aid. Ulyanovsk; 2016 (in Russ.).
  32. Чумбуридзе В., Кикалишвили Т. Коморбидные состояния при хронической сердечной недостаточности: как оптимизировать лечение? Неотложная кардиология и кардиоваскулярные риски. 2018; 2 (1): 286–90.
  33. Lakomkin N., Sathiyakumar V., Wick B., Shen M., Jahangir A., Mir H. et al. Incidence and predictive risk factors of postoperative sepsis in orthopedic trauma patients. J. Orthop. Traumatol. 2017; 18 (2): 151–8. DOI: 10.1007/s10195-016-0437-4
****
  1. Comorbidity: addiction and other mental illnesses. Rockville, MD: United States Department of Health and Human Services, National Institutes of Health, National Institute of Drug Abuse; 2010 (in Russ.). www.wikichi.ru
  2. Putilina M.V. Comorbidity in elderly patients. Korsakov’s Journal of Neurology and Psychiatry. 2016; 116 (5): 106–11 (in Russ.). DOI: 10.17116/jnevro201611651106-111
  3. Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008; 8: 221. DOI: 10.1186/1471-2458-8-221
  4. Oganov R.G. The fight against cardiovascular diseases is a contribution of the state, civil society and individuals. IX All-Russian Forum "The health of the nation is the basis of Russia's prosperity." Moscow; 2015 (in Russ.).
  5. Australian Institute of Health and Welfare (AIHW): Chronic diseases and associated risk factors in Australia, 2006. Canberra, ACT; 2006.
  6. Lazebnik L.B. Polymorbidity and aging. News Honey and Pharmaceuticals. 2007; 1 (205) (in Russ.).
  7. Charlson M.E., Pompei P., Ales K.L., MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40: 373–83.
  8. Vertkin A.L., Khovasova N.S., Belyalov F. Comorbid patient. A guide for practitioners. Moscow: Eksmo; 2015 (in Russ.).
  9. Kochetova E.V. Evaluation of comorbidity in patients with chronic obstructive pulmonary disease. Tuberculosis and Lung Diseases. 2017; 95 (4): 11–4 (in Russ.). DOI: 10.21292/2075-1230-2017-95-4-11-14
  10. National guidelines for cardiovascular prevention. Cardiovascular Therapy and Prevention. 2011; 10 (6S2): 2–64 (in Russ.).
  11. Conroy R.M., Pyorala K., Fitzgerald A., Sans P., Menotti A., De Backer G. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europa: the SCORE project. Eur. Heart J. 2013; 24: 987–1003. DOI: 10.1016/s0195-668x(03)00114-3
  12. Oganov R.G., Denisov I.N., Simanenkov V.I., Bakulina N.V., Barbarash O.L., Boytsov S.A. et al. Comorbid pathology in clinical practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017; 16 (6): 5–56 (in Russ.). DOI: 10.15829/1728-8800-2017-6-5-56
  13. DuGoff E.H., Canudas-Romo V., Buttorff C., Bruce L., Anderson G. Multiple chronic conditions and life expectancy: a life table analysis. Med. Care. 2014; 52 (8): 688–94. DOI: 10.1097/MLR.0000000000000166
  14. Centers for Medicare & Medicaid Services. Chronic conditions overview. 2014. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics. Trends-and-Reports/Chronic Conditions/index.htm (accessed 20.07.2021)
  15. Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boytsov S.A. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66 (in Russ.). DOI: 10.15829/1728- 8800-2019-1-5-66
  16. Rocca W.A., Boyd C.M., Grossardt B.R., Bobo W.V., Finney L., Rutten J. et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin. Proc. 2014; 89 (10): 1336–49. DOI: 10.1016/j.mayocp.2014.07.010
  17. Chamberlain A.M., St Sauver J.L., Gerber Y., Manemann S.M., Boyd C.M., Dunlay S.M. et al. Multimorbidity in heart failure: a community perspective. Am. J. Med. 2015; 128 (1): 38–45. DOI: 10.1016/j.amjmed.2014.08.024
  18. Tolpygina S.N., Martsevich S.Yu., Deev A.D. The influence of concomitant diseases on a long-term prognosis in patients with chronic ischemic heart disease according to the prognosis IHD register. Rational Pharmacotherapy in Cardiology. 2015; 11 (6): 571–6 (in Russ.). DOI: 10.20996/1819-6446-2015-11-6- 571-576
  19. Oganov R.G. Vascular comorbidity: general approaches to prevention and treatment. Rational Pharmacotherapy in Cardiology. 2015; 11 (1): 4–7 (in Russ.).
  20. Akhmedova E.B., Mardanov B.U., Badeynikova K.K., Mamedov M.N. Study of the quality of life and parameters of the clinical and biochemical spectrum in patients with arterial hypertension and comorbid conditions. Rational Pharmacotherapy in Cardiology. 2017; 13 (1): 31–5 (in Russ.). DOI: 10.20996/1819-6446-2017-13-1-31-35
  21. Tavluyeva E.V., Yarkovskaya A.P., Barbarash O.L. The relationship of diabetes mellitus with pro-inflammatory status in women and men with STEMI. Complex Issues of Cardiovascular Diseases. 2014; 1: 42–6 (in Russ.).
  22. Zykov M.V. Features of the course and risk stratification of complications of acute coronary syndrome in combination with renal dysfunction and different treatment strategies (literature review). Complex Issues of Cardiovascular Diseases. 2015; 3: 68–78 (in Russ.).
  23. Sumin A.N., Korok E.V., Shcheglova A.V., Barbarash O.L. Comorbidity in patients with coronary heart disease: gender characteristics. Rational Pharmacotherapy in Cardiology. 2017; 13 (5): 622–9 (in Russ.). DOI: 10.20996/1819-6446-2017-13-5-622-629
  24. Shikhverdiev N.N., Ushakov D.I., Peleshok A.S., Krivopalov V.A., Sizenko V.V. New approaches to risk stratification in elderly cardiac surgery patients. Clinical and Experimental Surgery. Petrovsky Journal. 2019; 7 (1): 23–7 (in Russ.). DOI: 10.24884/0042-4625- 2019-178-1-17-20
  25. Khasanova L.B., Komarova I.S., Andreeva N.V., Zhelnov V.V. Influence of multimorbidity on adherence to treatment of patients with myocardial infarction. Scientific News. 2018; 11: 86–91 (in Russ.).
  26. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 2011; 364: 2187–98. DOI: 10.1056/NEJMoa1103510
  27. Keymel S., Hellhammer K., Zeus T., Merx M., Kelm M., Steiner S. et al. Severe aortic valve stenosis in the elderly: high prevalence of sleep-related breathing disorders. Clin. Interv. Aging. 2015; 10: 1451–6. DOI: 10.2147/CIA.S87189
  28. Lindman B.R., Patel J.N. Multimorbidity in older adults with aortic stenosis. Clin. Geriatr. Med. 2016; 32: 305–14. DOI: 10.1016/j.cger.2016.01.006
  29. Forman D.E., Maurer M.S., Boyd C., Brindis R., Salive M.E., Horne F.M., Rich M.W. Multimorbidity in older adults with cardiovascular disease. J. Am. Coll. Cardiol. 2018; 71 (19): 2149–61. DOI: 10.1016/j.jacc.2018.03.022
  30. Min H., Avramovic S., Wojtusiak J., Khosla R., Fletcher R.D., Alemi F. et al. A comprehensive multimorbidity index for predicting mortality in intensive care unit patients. J. Palliat. Med. 2017; 20: 35–41. DOI: 10.1089/jpm.2015.0392
  31. Ефремова Е.В., Шутов А.М., Серов В.А., Мензоров М.В. Коморбидность в клинической медицине: учебно-методическое пособие. Ульяновск: УлГУ; 2016. Efremova E.V., Shutov A.M., Serov V.A., Menzorov M.V. Comorbidity in clinical medicine: teaching aid. Ulyanovsk; 2016 (in Russ.).
  32. Chumburidze V., Kikalishvili T. Comorbidities in heart failure: how to optimize treatment? Emergency Cardiology and Cardiovascular Risks. 2018; 2 (1): 286–90 (in Russ.).
  33. Lakomkin N., Sathiyakumar V., Wick B., Shen M., Jahangir A., Mir H. et al. Incidence and predictive risk factors of postoperative sepsis in orthopedic trauma patients. J. Orthop. Traumatol. 2017; 18 (2): 151–8. DOI: 10.1007/s10195-016-0437-4

About Authors

  • Dmitriy M. Pelekh, Cand. Med. Sci., Researcher, Cardiologist; ORCID
  • Tat’yana G. Nikitina, Dr. Med. Sci., Professor, Head of Department of Cardiology of Acquired Heart Diseases; ORCID
  • Knar S. Gulyan, Cand. Med. Sci., Cardiologist; ORCID
  • Aleksandr A. Fadeev, Cand. Tech. Sci., Head of Laboratory for the Application of Polymers in Cardiovascular Surgery; ORCID
  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Director; ORCID

 If you found mistakes, select text and press Alt+A